Role of cell-cycle regulators in lung cancer

Journal of Cellular Physiology

Volumn 205, Issue 3, 2005, Pages 319-327

  Caputi, Mario ^a   Russo, Giuseppe ^c,d   Esposito, Vincenzo ^b   Mancini, Alessandro ^a   Giordano, Antonio ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^c Temple University   (United States)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DEATH ASSOCIATED PROTEIN KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN BCL 2; PROTEIN P107; PROTEIN P130; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P19; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; RETINOBLASTOMA PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR E2F; UNINDEXED DRUG; UVOMORULIN;

APOPTOSIS; CANCER GROWTH; CAUSE OF DEATH; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; DEPHOSPHORYLATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CELL CYCLE PROTEINS; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS;

EID: 27744443763     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20424     Document Type: Review

References (100)

1. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. 1998. The p53 network. J Biol Chem 273(1):1-4.
2. Baldi A, Esposito V, De Luca A, Howard CM, Mazzarella G, Baldi F, Caputi M, Giordano A. 1996. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 2(7):1239-1245.
3. Baldi A, Esposito V, De Luca A, Fu Y, Meoli I, Giordano GG, Caputi M, Baldi F, Giordano A. 1997. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 3(10):1691-1697.
4. Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. 2002. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 21(23):3814-3825.
5. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8(8):816-824.
6. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98(24):13790-13795.
7. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. 1987. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326(6112):515-517.
8. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, Baldi F, Giordano A. 1998. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: Relationship to survival. Am J Respir Cell Mol Biol 18(2):213-217.
9. Chang TH, Szabo E. 2002. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8(4):1206-1212.
10. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1(4):304-313.
11. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. 2003. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2(2):107-116.
12. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. 1994. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54(21):5556-5560.
13. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Hicheli P, Caputi M, Giordano GG, Giordano A. 2000. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 60(2):372-382.
14. Claudio PP, Stiegler P, Howard CM, Bellan C, Minimo C, Tosi GM, Rak J, Kovatich A, De Fazio P, Micheli P, Caputi M, Leoncini L, Kerbel R, Giordano GG, Giordano A. 2001. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res 61(2):462-468.
15. Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev 7(12A):2392-2404.
16. D'Amico TA, Massey M, Herndon JE II, Moore MB, Harpole DH, Jr. 1999. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117(4):736-743.
17. D'Amico TA, Aloia TA, Moore MB, Herndon JE II, Brooks KR, Lau CL, Harpole DH, Jr. 2000. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 69(3):882-886.
18. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE II, Kinch MS, Harpole DH, Jr. 2001. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72(4):1144-1148.
19. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. 1998. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 153(3):963-972.
20. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, Warburton D. 1997. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol 273(5 Pt 1):L941-L949.
21. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. 1997a. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57(16):3381-3385.
22. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, Caputi M, Giordano A. 1997b. Prognostic value of p53 in non-small cell lung cancer: Relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 28(2):233-237.
23. Esposito V, Groeger AM, De Luca L, Di Marino M, Santini D, Marchei P, Baldi F, Wolner E, Baldi A. 2002. Expression of surface protein receptors in lung cancer. Anticancer Res 22(6C):4039-4043.
24. Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, Mineo TC, Persichetti P, Liuzzi G, Montesarchio V, Wolner E, Baldi F, Groeger AM. 2004. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 57(1):58-63.
25. Ewen ME, Xing YG, Lawrence JB, Livingston DM. 1991. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66(6):1155-1164.
26. Eymin B, Gazzeri S, Brambilla C, Brambilla E. 2002. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21(17):2750-2761.
27. Feld R, Rubinstein LV, Weisenberger TH. 1984. Sites of recurrence in resected stage I non-small-cell lung cancer: A guide for future studies. J Clin Oncol 2(12):1352-1358.
28. Fong KM, Sekido Y, Gazdar AF, Minna JD. 2003. Lung cancer. 9: Molecular biology of lung cancer: Clinical implications. Thorax 58(10):892-900.
29. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. 2000. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20(16):6147-6158.
30. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I. 2001. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98(24):13784-13789.
31. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. 1998. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16(4):497-504.
32. Goodwin LO, Mason JM, Hajdu SI. 2001. Gene expression patterns of paired bronchioloalveolar carcinoma and benign lung tissue. Ann Clin Lab Sci 31(4):369-375.
33. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, Richards WG, Sugarbaker DJ, Bueno R. 2002. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62(17):4963-4967.
34. Gorgpulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. 2002. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198(2):142-156.
35. Gouyer V, Gazzeri S, Bolon I, Drevet C, Brambilla C, Brambilla E. 1998. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 18(2):188-196.
36. Groeger AM, Caputi M, Esposito V, De Luca A, Bagella L, Pacilio C, Klepetko W, Giordano GG, Baldi F, Kaiser HE, Wolner E, Giordano A. 1999. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 118(3):529-535.
37. Groeger AM, Caputi M, Esposito V, Baldi A, Rossiello R, Santini D, Mancini A, Kaiser HE, Baldi F. 2000. Expression of p21 in non small cell lung cancer relationship with PCNA. Anticancer Res 20(5A):3301-3305.
38. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A, Wolner E. 2004. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 44(1):54-63.
39. Harpole DH, Jr., Herndon JE II, Young WG, Jr., Wolfe WG, Sabiston DC, Jr. 1995. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 76(5):787-796.
40. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P. 2002. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21(50):7749-7763.
41. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, Norgaard P. 1997. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 94(13):6933-6938.
42. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. 1994. Retinoblastoma protein expression in lung cancer: An immunohistochemical analysis. Oncology 51(6):544-551.
43. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van't Veer LJ, Bernards R. 1995. E2F-5, a new E2F family member that interacts with p130 in vira. Mol Cell Biol 15(6):3082-3089.
44. Jiang H, Lin J, Young SM, Goldstein NI, Waxman S, Davila V, Chellappan SP, Fisher PB. 1995. Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate. Oncogene 11(6):1179-1189.
45. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, Kato H. 2001. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34(2):207-218.
46. Kandasamy K, Srivastava RK. 2002. Role of the phosphatidylinositol 3′-kinase/ PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62(17):4929-4937.
47. Kang MJ, Park BJ, Byun DS, Park JI, Kim HJ, Park JH, Chi SG. 2000. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin Cancer Res 6(5):1767-1771.
48. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. 1998. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 79(3):215-220.
49. Kawamata N, Miller CW, Koeffler HP. 1995. Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers. Mol Carcinog 14(4):263-268.
50. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T. 1998. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 153(2):505-513.
51. Kaye FJ. 2002. RB and cyclin dependent kinase pathways: Defining a distinction between RB and p16 loss in lung cancer. Oncogene 21(45):6908-6914.
52. Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, Lee JD. 1999. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 81(1):127-132.
53. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. 2003. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22(14):2192-2205.
54. Kirsch DG, Kastan MB. 1998. Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 16(9):3158-3168.
55. Lam EW, La Thangue NB. 1994. DP and E2F proteins: Coordinating transcription with cell cycle progression. Curr Opin Cell Biol 6(6):859-866.
56. Li R, Waga S, Hannon GJ, Beach D, Stillman B. 1994. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371(6497):534-537.
57. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H. 2001. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71(3):949-954; discussion 954-955.
58. MacLachlan TK, Sang N, Giordano A. 1995. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5(2):127-156.
59. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J. 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science 288(5470):1425-1429.
60. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, La Rocca R, Merlo G, Chella A, Angeletti CA, Dalla Palma P, Bevilacqua G. 1998. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 75(2):187-192.
61. Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ, Takahashi T. 2001. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 61(14):5362-5365.
62. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A. 1993. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 8(9):2561-2566.
63. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP. 2002. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 33(1):17-21.
64. Milligan SA, Nopajaroonsri C. 2001. Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res 21(1A):39-44.
65. Minimo C, Bibbo M, Claudio PP, De Luca A, Giordano A. 1999. The role of pRb2/ p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies. Pathol Res Pract 195(2):67-70.
66. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH. 1999. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 19(5):3916-3928.
67. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. 2000. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 6(10):4055-4063.
68. Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC. 2002. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 62(11):3244-3250.
69. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo M, Curran J, Han S, Sidransky D, Buetow K, Madden SL, Jen J. 2001. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA 98(26):15203-15208.
70. Paggi MG, Baldi A, Bonetto F, Giordano A. 1996. Retinoblastoma protein family in cell cycle and cancer: A review. J Cell Biochem 62(3):418-430.
71. Parry D, Mahony D, Wills K, Lees E. 1999. Cyclin D-CDK subunit arrangement is dependent on the availabiHty of competing INK4 and p21 class inhibitors. Mol Cell Biol 19(3):1775-1783.
72. Powell CA, Spira A, Derti A, DeLisi C, Liu G, Borczuk A, Busch S, Sahasrabudhe S, Chen Y, Sugarbaker D, Bueno R, Richards WG, Brody JS. 2003. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol 29(2):157-162.
73. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, Stillman B. 1987. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 326(6112):517-520.
74. Reeve JG, Xiong J, Morgan J, Bleehen NM. 1996. Expression of apoptosis-regulatory genes in lung tumour cell lines: Relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 73(10):1193-1200.
75. Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, Hagiwara K, Hussain SP, Xiong Y, Demetrick DJ, Harris CC. 1996. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer 65(6):734-739.
76. Russo G, Claudio PP, Fu Y, Stiegler P, Yu Z, Macaluso M, Giordano A. 2003. pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene 22(44):6959-6969.
77. Salgia R, Skarin AT. 1998. Molecular abnormalities in lung cancer. J Clin Oncol 16(3):1207-1217.
78. I arrest checkpoint in response to DNA damage. Mol Cell Biol 18(1):378-387.
79. Sherr CJ. 1996. Cancer cell cycles. Science 274(5293):1672-1677.
80. Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM, Chittenden T. 1992. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68(1):157-166.
81. Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyooka S, Minna JD, Chaudhary PM, Gazdar AF. 2002. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21(55):8510-8514.
82. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H. 2002. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20(18):3865-3871.
83. Shopland DR. 1995. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 103(Suppl 8):131-142.
84. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, Putt ME, Kaiser LR, Albelda SM. 2003a. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2(3):291-298.
85. Singhal S, Amin KM, Kruklitis R, Marshall MB, Kucharczuk JC, DeLong P, Litzky LA, Kaiser LR, Albelda SM. 2003b. Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther 2(5):566-571.
86. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. 2000. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60(15):4000-4004.
87. Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, Nishiwaki Y. 1999. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67(4):927-932.
88. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, ElNaggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Jr., Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. 2003. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101.
89. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, Matsuda H. 1998. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 79(2):111-115.
90. Vairo G, Livingston DM, Ginsberg D. 1995. Functional interaction between E2F-4 and p130: Evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev 9(7):869-881.
91. Volm M, Koomagi R, Mattern J, Stammler G. 1997. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 75(12):1774-1778.
92. Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeier A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC. 1998. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 17(21):2779-2785.
93. Waga S, Hannon GJ, Beach D, Stillman B. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369(6481):574-578.
94. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS. 2002. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62(11):3005-3008.
95. Yanagisawa K, Uchida K, Nagatake M, Masuda A, Sugiyama M, Saito T, Yamaki K, Takahashi T, Osada H. 2000. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Oncogene 19(19):2305-2311.
96. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T. 1998. p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas. Cancer Res 58(5):1042-1047.
97. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, Smith DI, Liu W. 1999. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18(8):1629-1633.
98. 1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 32(1):27-38.
99. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E. 1993. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7(7A):1111-1125.
100. Zochbauer-Muller S, Gazdar AF, Minna JD. 2002. Molecular pathogenesis of lung cancer. Annu Rev Physiol 64:681-708.